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Purpose: The aim of this study was to identify the most precise and clinically practi-
cable parameters that predict future oral hypoglycemic agent (OHA) failure in pa-
tients with type 2 diabetes, and to determine whether these parameters are valuable 
in various subgroups. Materials and Methods: We took fasting blood samples from 
231 patients for laboratory data and standard breakfast tests for evaluation of pancre-
atic beta-cell function. Hemoglobin A1c (HbA1c) levels were tested, and we collect-
ed data related to hypoglycemic medications one year from the start date of the 
study. Results: Fasting C-peptide, postprandial insulin and C-peptide, the difference 
between fasting and postprandial insulin, fasting beta-cell responsiveness (M0), post-
prandial beta-cell responsiveness (M1), and homeostasis model assessment-beta 
(HOMA-B) levels were significantly higher in those with OHA response than in 
those with OHA failure. The area under the curve (AUC) of the receiver operating 
characteristic (ROC) measured with postprandial C-peptide to predict future OHA 
failure was 0.720, and the predictive power for future OHA failure was the highest of 
the variable parameters. Fasting and postprandial C-peptide, M0, and M1 levels 
were the only differences between those with OHA response and those with OHA 
failure among diabetic subjects with low body mass index, high blood glucose level, 
or long-standing diabetes. Conclusion: In conclusion, postprandial C-peptide was 
most useful in predicting future OHA failure in type 2 diabetic subjects. However, 
these parameters measuring beta-cell function are only valuable in diabetic subjects 
with low body mass index, high blood glucose level, or long-standing diabetes.
Key Words:    Type 2 diabetes, beta-cell function, OHA failure, standard breakfast 
test, C-peptide
INTRODUCTION
Oral hypoglycemic agents (OHA) have been a major modality for glucose control 
in patients with type 2 diabetes for over 50 years. However, OHA treatment failure 
is a common problem in the management of type 2 diabetes. Both patient- and dis-
ease-related factors can contribute to OHA failure. Poor compliance with lifestyle Seung Won Lee, et al.
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ferred to other hospitals, 10 withdrew their participation, and 
14 were lost to follow-up without cause. For the remaining 
182 patients, hemoglobin A1c (HbA1c) levels were tested and 
data regarding hypoglycemic medications at one year from the 
start date of the study were collected.
Standard breakfast test
Blood specimens for plasma insulin, C-peptide, and blood 
glucose levels were drawn after an overnight fast and 2 h 
after an individually composed breakfast meal. Plasma pro-
insulin was tested only from fasting blood specimens. In or-
der to exclude the influence of previous oral hypoglycemic 
agents or basal insulin on laboratory test results, all subjects 
discontinued previous medications and were administered a 
short-acting insulin analog (glulisine, Aventis Pharma) with 
premeal subcutaneous injections during the three days be-
fore testing. The calorie counts of breakfast for each patient 
were calculated according to the following method:7,8 Car-
bohydrates, proteins, and fat comprised 60%, 20%, and 20% 
of the total calories, respectively. Breakfast accounted for 
30% of each day’s total calories.
Laboratory methods
Blood glucose concentrations were measured using a glucose 
oxidase technique (Beckman, Fullerton, CA, USA). HbA1c 
concentrations were analyzed using high-performance liq-
uid chromatography (Variant II, Bio-Rad, Hercules, CA, 
USA). Insulin and C-peptide concentrations were measured 
by radioimmunoassay (Daiichi RI Co., Tokyo, Japan). Proin-
sulin concentrations were measured by radioimmunoassay 
(catalog no. HPI-15K; Millipore, St. Charles, MO, USA). 
This assay showed <0.1% cross-reactivity to both human 
insulin and C-peptide.
Data processing
Markers of insulin sensitivity and beta-cell function were 
determined by the quantitative insulin sensitivity check in-
dex (QUICKI) and homeostasis model assessment-beta 
(HOMA-B) index, respectively.9,10 Fasting beta-cell respon-
siveness (M0) represents the ability of fasting glucose to 
stimulate beta-cell secretion, and postprandial beta-cell re-
sponsiveness (M1) represents the ability of postprandial 
glucose to step up beta-cell secretion; these values were 
calculated using the formula of Hovorka, et al.11 with some 
modification: M0=100×fasting C-peptide (μg/L)/fasting 
glucose concentration (mg/dL), and M1=100×[postprandial 
2-h C-peptide concentration (μg/L)-fasting C-peptide con-
change is thought to be a major reason for poor responses 
to OHA treatment.1,2 Deterioration of beta-cell function is 
the strongest disease-related factor. In several longitudinal 
studies, beta-cell function of patients with type 2 diabetes 
declined continuously over time.3,4 At diagnosis, beta-cell 
function was already reduced by 50%, and further deterio-
ration occurred regardless of therapy.3 The mechanisms of 
action of almost all OHAs are insulin-dependent, and they do 
not decrease the blood glucose level when beta-cell function 
has severely deteriorated. Thus, deterioration of beta-cell 
function is an important cause of OHA failure in patients 
with type 2 diabetes.
Diagnosis of beta-cell dysfunction in patients with type 2 
diabetes plays an important role when OHA failure is sus-
pected or new treatment modalities are used. Insulin, C-
peptide, and proinsulin are secreted from pancreatic beta-
cells and are the key protein hormones that reflect beta-cell 
function.5 However, insulin and C-peptide levels, as well as 
different indexes taking into account fasting plasma insulin 
in relation to fasting blood glucose, are not clear in mea-
surements of insulin secretion and clinical decisions.
The aim of this study was to identify the most precise and 
clinically practicable parameters that predict future OHA 
failure in patients with type 2 diabetes, and to determine 




We recruited 267 patients with diabetes who were managed 
with oral hypoglycemic agents or insulin in the Endocrinol-
ogy Department of Kwandong University Myongji Hospi-
tal, located in Goyang, Korea, between February and May 
2009. Thirty-six of these patients were excluded for the fol-
lowing reasons: type 1 diabetes, pregnant or breast-feeding, 
acute or chronic infectious diseases, or general treatment 
with glucocorticoids. The ethics committee approved the 
study protocol. All patients provided informed consent.
The remaining 231 patients (115 women) gave fasting blood 
samples for laboratory data and the standard breakfast test for 
evaluation of pancreatic beta-cell function. We managed the 
study participants according to a consensus algorithm for the 
management of hyperglycemia in type 2 diabetes from the 
American Diabetes Association and The European Association 
for the Study of Diabetes.6 We were unable to maintain contact 
with 49 patients during follow-up period because 25 trans-Parameters Measuring Beta-Cell Function
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ues (interquartile range) of age and diabetic duration were 
61.5 (47.0-71.0) and 9.0 (2.0-15.0) years, respectively. Fif-
ty-seven patients had been treated with insulin injections 
(39 patients with insulin and OHA, 18 patients with insulin 
only) at one year from the start date of the study. The medi-
an insulin dose was 30.0 (22.0-38.0) units. One hundred and 
twenty-five patients were treated with OHA only: monother-
apy in 13 patients, double combination therapy in 78, and 
triple combination therapy in 34.
Comparison of baseline insulin secretion parameters of 
those with oral hypoglycemic response versus failure
In total, 182 patients (excluding the 49 lost to follow-up) 
were divided into those with OHA response (n=52) or OHA 
failure (n=130) according to insulin administration or the 
follow-up HbA1c 7.0% cutoff. There was no difference in 
gender, age, weight, or other baseline clinical characteristics 
between the two groups. Only the duration of diabetes was 
significantly higher in those with OHA failure than in those 
with OHA response (Table 1). In laboratory parameters rep-
resenting the insulin secretion reserve of pancreatic beta-
cells, fasting C-peptide, postprandial insulin and C-peptide, 
the differences between fasting and postprandial insulin, 
M0, M1, and HOMA-beta levels were significantly higher 
in those with OHA response than in those with OHA fail-
ure. However, fasting proinsulin, fasting insulin, and insulin 
sensitivity indices (HOMA-IR and QUICKI) did not differ 
between the two groups (Table 2).
Prediction model ROC curve for OHA failure
The AUC of the ROC measured with postprandial C-pep-
tide to predict future OHA failure was 0.720, and the pre-
dictive power for future OHA failure was the highest of the 
variable parameters representing pancreatic beta-cell func-
tion. The AUC of the ROC measured with M0, fasting C-
peptide, HOMA-beta, proinsulin, M1, insulin difference, 
and postprandial insulin were 0.659, 0.637, 0.589, 0.547, 
0.655, 0.647, and 0.633, respectively.
When the postprandial C-peptide cutoff dividing those 
with OHA response and failure was 1.09 nmol/L (3.3 ng/
mL), the sensitivity and specificity of the diagnosis of OHA 
failure were 67.3% and 65.4%, respectively. When the fast-
ing C-peptide cutoff was 0.57 nmol/L (1.57 ng/mL), the 
sensitivity and specificity of the diagnosis of OHA failure 
were 59.6% and 58.5%, respectively. The sensitivity and 
specificity of the diagnosis of OHA failure with an M0 cut-
off of 1.03 were 65.4% and 63.8%, respectively. The sensi-
centration (μg/L)]/[postprandial 2-h glucose concentration 
(mg/dL)-fasting glucose concentration (mg/dL)]. QUICKI 
was calculated as 1/[log fasting insulin (μU/mL)+log fast-
ing glucose (mg/dL)], and HOMA-beta as [20×fasting in-
sulin (μU/mL)]/[fasting glucose (mmol/L)-3.5].
Hypertension was defined as systolic blood pressure of 140 
mmHg or greater, diastolic blood pressure of 90 mmHg or 
greater, or use of antihypertensive medication.12 Dyslipidemia 
was defined as triglycerides of 1.3 mmol/L or greater, high-
density lipoprotein cholesterol of 1.0 mmol/L or less in men 
and 1.3 mmol/L or less in women, or use of lipid-lowering 
agents.13 Diabetic retinopathy was defined as a diagnosis of 
nonproliferative retinopathy or proliferative retinopathy by an 
ophthalmologist. Diabetic nephropathy was defined as an al-
bumin to creatinine ratio of 300 μg/mg in a random urine test 
or an estimated glomerular filtration rate by the Cockroft-
Gault equation of 60 mL/min or less per 1.73 m2 body sur-
face area.14 Regular physical activity was defined as weekly 
exercise time of 150 min or greater.15 Drinkers were defined 
as those with weekly alcohol intake of 210 g or greater in 
men and 105 g or greater in women.14 OHA failure was de-
fined as insulin use for control of blood glucose or HbA1c of 
7.0% or greater with maximal doses of combined OHAs (two 
or more of metformin, sulfonylurea, or thiazolidinedione).
 Statistical analyses
Several variables, including HbA1c, blood glucose, insulin, 
C-peptide, HOMA-IR, HOMA-beta, and proinsulin, were 
not normally distributed in the Shapiro-Wilk test. Logarith-
mic transformation was used to normalize them, and the 
variables were applied in the following analyses. A logistic 
regression analysis was used to compare the clinical and 
laboratory variables between those who responded to OHA 
and those in which it failed after adjusting for gender, age, 
and duration of diabetes. The receiver operating character-
istic (ROC) and the area under the curve (AUC) were mea-
sured for estimation of the prediction power of future OHA 
failure by various insulin secretion parameters. We divided 
subgroups according to body mass index (BMI), fasting 
glucose, and duration of diabetes, and compared insulin se-
cretion parameters by logistic regression analysis after ad-
justing for gender, age, and duration of diabetes.
RESULTS
 
Ninety-two subjects were female (50.5%). The median val-Seung Won Lee, et al.
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peptide (0.55 and 0.36-0.85 vs. 0.34 and 0.25-0.61 nmol/L; 
p=0.021), M0 (1.24 and 0.66-1.49 vs. 0.66 and 0.41-1.10; 
p=0.002), HOMA-beta (26.9 and 13.2-55.3 vs. 17.5 and 
8.1-41.6; p=0.019), postprandial Cpeptide (1.35 and 0.95-
1.77 vs. 0.72 and 0.46-1.15 nmol/L; p=0.005), and M1 
(1.92 and 0.95-4.15 vs. 0.83 and 0.37-1.79; p=0.013). In 
contrast, in the subgroup with high BMIs (≥25), the levels 
of insulin secretion parameters were higher than in those 
with OHA failure, but there was no significant difference 
between OHA response and failure (Fig. 1).
Comparison of baseline insulin secretion parameters of 
those with OHA response versus failure in subgroup 
analysis according to fasting glucose levels
Among the 182 patients with follow-up HbA1c, 77 patients 
had fasting blood glucose levels of 10 mmol/L or greater. In 
patients with high fasting blood glucose, those with OHA 
response versus OHA failure have the following character-
tivity and specificity of the diagnosis of OHA failure with 
an M1 cutoff of 1.33 was 61.5% and 61.5%, respectively. 
The lowest values of fasting and postprandial C-peptide, 
M0, and M1 in those with OHA response were 0.18 nmol/L 
(0.56 ng/mL), 0.45 nmol/L (1.37 ng/mL), 0.32, and -19.21, 
respectively. When the HbA1c cutoff dividing OHA response 
and failure was 8.7%, the sensitivity, specificity, and AUC 
of the ROC were 60.8%, 61.5%, and 0.673. When the dura-
tion of diabetes cutoff was 7.5 years, these values were 
57.7%, 57.7%, and 0.611.
Comparison of baseline insulin secretion parameters of 
those with OHA response versus failure in subgroup 
analysis according to BMI
Of the 182 patients with follow-up HbA1c, 115 had BMIs of 
25.0 or less. In patients with low BMIs (<25.0), those with 
OHA response versus OHA failure have the following char-
acteristics: medians and interquartile ranges of fasting C-
Table 1. Comparison of Baseline Clinical Parameters of OHA Responders versus Failures
OHA responder OHA failure p value
Number 52 130
Anthropometric variables
    Sex (female %) 42.3 53.8 0.137
    Age (yrs)   58.0 (44.5-71.0)   62.0 (48.0-70.0) 0.098
    Duration of diabetes (yrs)     2.0 (0.0-10.0)   10.0 (4.0-17.0) <0.0001
    Systolic blood pressure (mmHg) 126.5 (116.8-137.3) 120.0 (111.0-132.0) 0.049
    Diastolic blood pressure (mmHg)   79.5 (70.0-80.0)   76.0 (70.0-84.0) 0.982
    Body mass index (kg/m
2)*   23.7 (22.2-27.0)   23.3 (21.0-26.4) 0.283
Historical variables
    Current smoking (%) 19.2 19.2 0.529
    Regular physical activity (%) 32.0 24.6 0.279
    Drinker (%) 14.6 16.1 0.588
    Hypertension (%) 36.5 25.4 0.032
    Dyslipidemia (%) 92.3 84.6 0.057
    History of sroke (%)   9.6   9.2 0.398
    History of ischemic heart disease (%)   9.6 10.8 0.890
    Diabetic retinopathy (%) 20.0 28.8 0.425
    Diabetic nephropathy (%) 13.5 20.0 0.830
Antihypoglycemic agents
    Insulin (%)   6.5 24.6 0.098
    Metformin (%) 33.3 52.7 0.129
    Sulonylurea (%) 35.6 57.1 0.104
    Thiazolidinedione (%)   8.9   9.8 0.439
    α-glucosidase inhibitor (%)   2.2 12.5 0.160
    Meglitinide (%)   4.4   6.3 0.568
    DPP-4 inhibitor (%)   2.2   0.9 0.517
OHA, oral hypoglycemic agent; DPP, dipeptidyl peptidase-4. 
Data are expressed as medians (interquartile range) and percentages. 
p was calculated adjusting for gender, age, and duration of diabetes. 
*p was calculated from log-transformed data.Parameters Measuring Beta-Cell Function
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Comparison of baseline insulin secretion parameters of 
OHA response versus failure in subgroup analysis 
according to the duration of diabetes
Of the 182 patients with follow-up HbA1c, 119 patients had 
had diabetes for over five years. In patients with long dia-
betic duration, those with OHA response versus OHA fail-
ure have the following characteristics: medians and inter-
quartile ranges of fasting C-peptide (0.72 and 0.55-1.07 vs. 
istics: medians and interquartile ranges of M0 (0.88 and 
0.47-1.23 vs. 0.51 and 0.35-0.89; p=0.032), postprandial in-
sulin (104.6 and 69.7-259.3 vs. 75.9 and 42.2-171.4 pmol/L; 
p=0.028), postprandial C-peptide (1.11 and 0.76-1.90 vs. 
0.73 and 0.46-1.11 nmol/L; p=0.007), and M1 (1.80 and 0.95-
3.93 vs. 0.67 and 0.26-1.59; p=0.009). In the subgroup with 
low fasting blood glucose, however, there was no signifi-
cant difference between OHA response and failure (Fig. 2).
Table 2. Comparison of Baseline Laboratory Parameters of OHA Responders versus Failures
OHA responder OHA failure p value
Number 52 130
Baseline HbA1c (%)*     8.2 (6.7-10.7)     9.3 (7.6-10.8) 0.003
Follow-up HbA1c (%)*     6.5 (6.0-6.8)     8.3 (7.4-9.4) <0.0001
Baseline fasting values
    Glucose (mmol/L)*     8.3 (6.6-10.8)     9.8 (7.2-12.2) 0.012
    Insulin (pmol/L)*   50.4 (30.6-87.2)   45.1 (23.5-93.1) 0.179
    C-peptide (nmol/L)*   0.61 (0.41-0.89)   0.47 (0.27-0.75) 0.015
    M0*   1.27 (0.75-1.84)   0.79 (0.43-1.41) 0.002
    Proinsulin (pmol/L)*   19.8 (11.8-31.7)   16.8 (11.6-27.6) 0.521
    Proinsulin-insulin ratio*   0.39 (0.20-0.68)   0.44 (0.23-0.65) 0.437
Baseline postprandial values
    Glucose (mmol/L)*   14.6 (10.1-16.8)   16.8 (12.8-19.7) 0.009
    Insulin (pmol/L)* 164.7 (97.0-261.3) 114.9 (52.9-209.3) 0.017
    C-peptide (nmol/L)*   1.35 (0.96-1.98)   0.82 (0.52-1.23) 0.001
Baseline difference values
    Insulin (pmol/L)* 109.1 (45.5-210.7)   53.8 (17.7-116.8) 0.047
    C-peptide (nmol/L)*   0.81 (0.33-1.22)   0.35 (0.17-0.70) 0.058
    M1*   1.92 (0.90-4.20)   0.88 (0.38-2.22) 0.007
Baseline HOMA-IR*   2.66 (1.75-4.63)   2.70 (1.44-4.80) 0.766
Baseline HOMA-beta*   33.9 (14.3-72.5)   23.4 (9.8-50.5) 0.017
Baseline QUICKI 0.330 (0.305-0.351) 0.329 (0.304-0.361) 0.658
OHA, oral hypoglycemic agent; HOMA-IR or HOMA-beta, homeostasis model assessment of insulin resistance and beta-cell function; 
QUICKI, quantitative insulin sensitivity check index. 
Data are expressed as medians (interquartile range) and percentages. 
p was calculated adjusting for gender, age, and duration of diabetes. 
*p was calculated from log-transformed data.
Fig. 1. Comparison of baseline insulin secretion parameters of OHA responders versus failures in subgroup analysis according to body 
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drawback, different insulin concentrations are required. Ad-
ditionally, the need for reaching and maintaining different 
steady states within the same experiment makes it impossi-
ble to perform routinely in clinical practice.
In clinical practice, only fasting samples or simple stimu-
lation tests, such as the OGTT, the glucagon stimulatory 
test, or the standard breakfast test, which are the most wide-
ly used and validated, may be used as parameters of insulin 
secretion. In these tests, mathematical handling of fasting 
levels of glucose, insulin, and C-peptide concentrations is the 
simplest method. Mathematical handling of the fasting levels 
has been used for the calculation of insulin sensitivity and 
secretion by introducing various indices, such as HOMA, 
fasting beta-cell responsiveness (M0), and QUICKI.9-11 How-
ever, these simplistic approaches do not give clues about 
the dynamic state of the relationship between insulin sensi-
tivity and secretion. To estimate beta-cell function, dynamic 
tests are more useful than fasting samples.
The most widely used test to evaluate insulin reserves is 
the glucagon stimulatory test. Its validity has been discussed, 
0.43 and 0.26-0.71 nmol/L; p=0.006), M0 (1.34 and 1.14-
2.13 vs. 0.76 and 0.44-1.36; p=0.001), postprandial C-pep-
tide (1.37 and 1.10-2.02 vs. 0.76 and 0.50-1.13 nmol/L; 
p=0.001), M1 (1.82 and 0.96-4.20 vs. 0.67 and 0.31-1.53; 
p=0.008), and C-peptide difference (0.85 and 0.31-1.22 vs. 
0.31 and 0.15-0.53 nmol/L; p=0.021). In the subgroup with 
short diabetic duration, however, there was no significant 
difference between those with OHA response and with 
OHA failure (Fig. 3).
DISCUSSION
   
The gold standard for measuring insulin sensitivity is the 
euglycemic hyperinsulinemic clamp technique,16 which is 
reproducible and sensitive. However, insulin secretion can-
not be evaluated from the euglycemic clamp. When using 
the clamp, it is thus necessary to perform another experi-
ment, such as a primed hyperglycemic glucose clamp or an 
intravenous glucose tolerance test.17 To circumvent this 
Fig. 2. Comparison of baseline insulin secretion parameters of OHA responders versus failures in subgroup analysis according to fasting 
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Fig. 3. Comparison of baseline insulin secretion parameters of OHA responders versus failures in subgroup analysis according to dura-
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one-year period. The sensitivity and specificity of basal C-
peptide levels of less than 0.9 nmol/L in patients with insu-
lin treatment were 83.6% and 78.9%, respectively. For 
postprandial values of less than 1.9 nmol/L, the sensitivity 
and specificity were 77.7% and 78.9%, respectively. The cut-
off values, sensitivity, and specificity of the Manzanares 
study were higher than those of our study. However, only 
patients with a high basal glucose (greater than 11.1 mmol/
L) were enrolled in the Manzanares study. If we had select-
ed patients with a high basal glucose (greater than 10.0 
mmol/L) for our study, the sensitivity and specificity would 
have been higher (data not shown). Thus, the results of our 
study can be generally applied to all diabetic subjects. The 
higher cutoff values found in the Manzanares study may be 
explained by higher BMI, racial differences, higher insulin 
resistance, or a combination of these factors.
In a previous study, C-peptide release in lean and over-
weight patients was found to be significantly lower in insu-
lin-treated than in OHA-treated patients, but this difference 
disappeared in obese patients.25 In our study, we observed 
the same relationship between obesity and values of beta-
cell functional parameters. Variations in insulin clearance, 
mainly in obese patients, and particularly those with excess 
abdominal fat, may modify the relationship between plas-
ma insulin values and insulin secretion. Abdominal obesity 
was inversely correlated with the hepatic extraction frac-
tion, and directly correlated with posthepatic delivery of in-
sulin.26 Thus, insulin hypersecretion in obese diabetes pa-
tients represents a diminution of peripheral insulin sensitivity 
rather than insulin secretion function of pancreatic beta-
cells. In fact, there was a marked difference in insulin sensi-
tivity indicators such as HOMA-IR and QUICKI between 
the groups with low and high BMI.
In contrast, the data of the subgroups divided by duration 
of diabetes or fasting plasma glucose levels differed from 
that of BMI. There was no significant difference in HOMA-
IR or QUICKI between groups divided by duration of dia-
betes or fasting plasma glucose levels (data not shown). In 
subjects with high fasting plasma glucose, pancreatic insu-
lin secretion was fully stimulated, as opposed to the sub-
maximal stimulation in subjects with low fasting plasma 
glucose. The plasma C-peptide response to intravenous glu-
cagon and to a standard test meal was markedly potentiated 
by acute hyperglycemia in type 2 diabetes mellitus. How-
ever, no further potentiation was obtained when the prestim-
ulatory blood glucose concentration rose above 12 mmol/L.27 
This suggests that maximal stimulation of beta-cells raises 
along with the methodological aspects of its interpreta-
tion.18 The glucagon test has the advantage of being a more 
reproducible stimulus and having much faster action on be-
ta-cells (peak values after 6 instead of 120 min), allowing a 
marked reduction in observation time. In contrast, the stan-
dard breakfast test has the advantage of being a greater 
physiological stimulus, avoiding the side effects of gluca-
gon injection. However, in clinical practice, both tests are 
useful in estimating beta-cell function. The standard break-
fast test could be an alternative to the glucagon stimulatory 
test; a good correlation of C-peptide increments in the two 
tests has been observed.19
The use of measurements related to the circulating insu-
lin concentration does not necessarily translate to informa-
tion on insulin secretion because only posthepatic insulin 
delivery is considered. The role of hepatic insulin extraction 
should also be taken into account if we are interested in 
evaluating beta-cell function. However, C-peptide is equi-
molarly released with insulin, not degraded in the liver, and 
has a 10-fold longer half-life.20 Therefore, C-peptide is con-
sidered to be a more reliable marker of pancreatic insulin 
secretion than insulin.
Hovorka, et al.21 proposed pancreatic responsiveness dur-
ing glucose stimulation (M1) and under basal conditions 
(M0) during the meal tolerance test, and reported a significant 
difference in these parameters between healthy and type 2 di-
abetic subjects. A key aspect of M0 and M1 is that C-peptide, 
a representative parameter of pancreatic beta-cell function, is 
corrected by plasma glucose levels. M0 was more valuable 
for predicting OHA failure than fasting C-peptide, and the 
predictive power for future OHA failure of M0 was compara-
ble to that of postprandial C-peptide. If only fasting samples 
are available, it has been suggested that M0 is the most valu-
able parameter for estimating beta-cell function.
Levels of proinsulin-like molecules are elevated in sub-
jects with type 2 diabetes or impaired glucose tolerance.22  It 
has been suggested that elevated proinsulin levels are a 
manifestation of beta-cell dysfunction rather than of in-
creased demand on the beta-cell. This may reflect beta-cell 
“stress”, with defective post-translational processing and/or 
accelerated granule secretion before processing is complet-
ed.23 We found no difference in fasting proinsulin levels or 
in the proinsulin to insulin ratio between those with OHA 
response and failure. Additional studies are necessary to 
identify the roles of proinsulin-like molecules in diabetes.
Manzanares, et al.24 studied the efficacy of a standard 
mixed meal to predict the need for insulin therapy over a Seung Won Lee, et al.
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perglycemic stress. Diabetes 1964;13:6-13.  
2. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. 
Secondary failure to treatment with oral antidiabetic agents in non-
insulin-dependent diabetes. Diabetes Care 1986;9:129-33. 
3. U.K. prospective diabetes study 16. Overview of 6 years’ therapy 
of type II diabetes: a progressive disease. U.K. Prospective Diabe-
tes Study Group. Diabetes 1995;44:1249-58. 
4. Festa A, Williams K, D’Agostino R Jr, Wagenknecht LE, Haffner 
SM. The natural course of beta-cell function in nondiabetic and 
diabetic individuals: the Insulin Resistance Atherosclerosis Study. 
Diabetes 2006;55:1114-20. 
5. Hutton JC. Insulin secretory granule biogenesis and the proinsulin-
processing endopeptidases. Diabetologia 1994;37 Suppl 2:S48-56. 
6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, 
Sherwin R, et al. Medical management of hyperglycemia in type 2 
diabetes: a consensus algorithm for the initiation and adjustment 
of therapy: a consensus statement of the American Diabetes Asso-
ciation and the European Association for the Study of Diabetes. 
Diabetes Care 2009;32:193-203. 
7. Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh 
YO. A new predictive equation for resting energy expenditure in 
healthy individuals. Am J Clin Nutr 1990;51:241-7. 
8. Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Williams 
textbook of endocrinology. 10th ed. Philadelphia: SAUNDERS; 
2003. 
9. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan 
G, et al. Quantitative insulin sensitivity check index: a simple, ac-
curate method for assessing insulin sensitivity in humans. J Clin 
Endocrinol Metab 2000;85:2402-10. 
10. Albareda M, Rodriguez-Espinosa J, Murugo M, de Leiva A, 
Corcoy R. Assessment of insulin sensitivity and beta-cell function 
from measurements in the fasting state and during an oral glucose 
tolerance test. Diabetologia 2000;43:1507-11. 
11. Hovorka R, Chassin L, Luzio SD, Playle R, Owens DR. Pancreatic 
beta-cell responsiveness during meal tolerance test: model assess-
ment in normal subjects and subjects with newly diagnosed nonin-
sulin-dependent diabetes mellitus. J Clin Endocrinol Metab 
1998;83:744-50. 
12. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, 
Izzo JL Jr, et al. The Seventh Report of the Joint National Com-
mittee on Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72. 
13. Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults. Executive Summary of The Third 
Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, And Treatment of High 
Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 
2001;285:2486-97. 
14. American Diabetes Association. Standards of medical care in dia-
betes--2006. Diabetes Care 2006;29 Suppl 1:S4-42. 
15. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratz-
ka LF, et al. 1999 update: ACC/AHA Guidelines for the Manage-
ment of Patients With Acute Myocardial Infarction: Executive 
Summary and Recommendations: A report of the American Col-
lege of Cardiology/American Heart Association Task Force on 
Practice Guidelines (Committee on Management of Acute Myo-
cardial Infarction). Circulation 1999;100:1016-30. 
16. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a 
method for quantifying insulin secretion and resistance. Am J 
Physiol 1979;237:E214-23. 
the predictive power of insulin secretion parameters, detect-
ing OHA failure.
Explaining the effect of diabetic duration on the predicting 
power of the parameters of beta-cell function is less clear. 
Among patients with OHA failure, the levels of fasting and 
postprandial C-peptide, M0, and M1 of patients with long 
duration of diabetes were markedly lower than those with 
shorter duration of diabetes. This may be due to the continu-
ous decrease in beta-cell function that occurs in long-stand-
ing diabetes. In contrast, the levels of these parameters did 
not differ between the two groups in those with OHA re-
sponse. The difference in beta-cell function between those 
with OHA response and those with OHA failure seemed to 
be pronounced in patients with long diabetic duration. 
This study has some limitations. Both patient- and disease-
related factors can contribute to OHA failure in type 2 diabe-
tes. We primarily evaluated the usefulness of insulin secre-
tion parameters in predicting OHA failure. Poor compliance 
with lifestyle change is thought to be a major reason for poor 
responses to OHA treatment; we did not relate the effects of 
lifestyle changes to the participants’ responses to OHA. In 
this study, we defined OHA failure as insulin use for control 
of blood glucose or HbA1c of 7.0% or greater with more 
than double OHA. The cutoff value of HbA1c was quite 
strict compared to one previous study.26 Some subjects with 
mild hyperglycemia may not have been true OHA failures. 
Future studies correcting these weak points are needed.
In conclusion, postprandial C-peptide was the most useful 
of the simple insulin secretion parameters for predicting fu-
ture OHA failure in type 2 diabetic subjects. M0 using fast-
ing samples was shown to be the next most useful. However, 
these parameters, which measure beta-cell function, are only 
valuable in diabetic subjects with low BMI, high blood glu-
cose level, or long-standing diabetes.
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